Date of event
Continuing Education Credits
Course Description / Needs Statement
The conference, Current Challenges in Clinical Management and Drug Development in NASH has been designed to bring together liver scientists (translational researchers and clinical investigators) with strong expertise in fatty liver disease. The goals of this symposium are to: i) allow both communities to learn about each other’s progresses, ii) review the most recent preclinical and clinical investigations in their respective field and, iii) promote the rapid emergence of novel and efficient therapeutic options.
- Rohit Loomba, MD
- Stephen A. Harrison, MD, FAASLD
The online live-streaming conference will have pre-recorded presentations for viewing along with live elements such as panel discussions, a poster session, and the opportunity to get your faculty questions answered in real time with both Chat and Q&A features available throughout the event.
Those interested in NASH are encouraged to submit abstracts for this conference starting Monday, April 5, 2021. Selected abstracts will be designated as oral abstract presentations during the conference. To learn more, visit the Abstract Submission and Policies section.
- Continuing Medical Education (CME): 9.50 AMA PRA Category 1 Credits™
- Maintenance of Certification: 9.50 ABIM MOC Points
Registration opens in May.
The conference has been designed to bring together liver scientists (translational researchers and clinical investigators) with strong expertise in fatty liver disease. The goals of this symposium are to: i) allow both communities to learn about each other’s progresses, ii) review the most recent preclinical and clinical investigations in their respective field and, iii) promote the rapid emergence of novel and efficient therapeutic options.
Upon completion of this activity, learners will be able to:
- Increases understanding of non-alcoholic fatty liver disease (NAFLD) to be more efficient in identifying current or future management strategies for patients.
- Enhanced knowledge and understanding of NAFLD to be informed of the most recent basic discoveries in the field.
- Learners will improve their knowledge and understanding of NAFLD.
- Physician Assistants
- Basic Scientists
- Graduate Students
- Patients Association
Continuing Medical Education (CME): 9.50 AMA PRA Category 1 Credits™
ABIM Maintenance of Certification (MOC): 9.50 ABIM MOC Points
Accreditation and Designation Statements
Continuing Medical Education (CME)
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 9.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
Claiming CME Credits and ABIM MOC Points
Physicians and other health care professionals seeking AMA PRA Category 1 Credits™ for this live continuing medical education activity must complete an evaluation by Thursday, July 15, 2021. A link to the CME evaluation will be emailed to attendees after the meeting.
Physicians seeking ABIM MOC points must complete the CME and MOC evaluation by Thursday, July 15, 2021. Requests for MOC after this date will not be honored. The MOC evaluation is included in the CME evaluation.
MOC Points will be reported to the ABIM by the end of July 2021 for attendees who successfully complete the MOC evaluation.
Abstract submissions are now being accepted. Submit your work for consideration.
Opens: Monday, April 5, 2021 at 9:00 AM ET
Closes: Friday, April 30, 2021 at 11:59 PM ET
Abstracts submitted will be reviewed by the Program Chairs for potential poster and/or oral abstract presentation. If selected, the presenting author will be required to accept the invitation to present, register for the conference, and provide current financial disclosure information.
Abstract notification will be sent to presenting authors by mid-May.
The title should be brief, but long enough to identify the nature of the study. Omit author names and medical degrees and institutional appointments in the title. The maximum for the title character count is 300.
The body of the abstract needs to include:
- A background
- Description of methods
- Summary of results obtained
- Statement of conclusion reached
There is a set 3,000 maximum character count for the abstract body.
You may include any supporting images/tables. Images and tables are not a part of the overall character count.
Accepted files: pdf, jpg, jpeg, png, csv, doc(x), and ppt under 5MB
Only one presenting and corresponding author may be selected – see author definitions below
- Co-Author – One of several authors who provided a significant contribution to the abstract.
- Corresponding Author – This author will receive all notifications regarding the abstract, and will be expected to make any changes requested by the abstract reviewers.
- Presenting Author – The author who will be presenting the poster at the meeting.
The maximum number of authors on an abstract is 30.
For questions about the abstract submission process, please send an email to email@example.com .
The initial responsibility for adherence to ethical guidelines lies with the responsible investigators submitting their research findings to AASLD meetings or journals. First, for reports of research using human subjects, provide assurance that (a) informed consent in writing was obtained from each patient and (b) the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the appropriate institutional review committee. Refer to individual patients by number, not by initials. HEPATOLOGY will only accept papers for review from liver transplant centers that explicitly state that no donor organs were obtained from executed prisoners or other institutionalized persons. Papers without such explicit statements will be returned without review.
Second, in studies involving animal experimentation, provide assurance that all animals received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals [PDF] prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985).
It is the policy of the American Association for the Study of Liver Diseases (AASLD) to ensure balance, independence, objectivity, and scientific rigor in all its individually or jointly provided educational programs. All faculty/authors participating in any AASLD sponsored programs, as well as planners and committee members are expected to disclose any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing medical education program.
All abstract authors must complete their own financial disclosure statement either disclosing all financial relationships with commercial interests or indicating that none exist. Submitting authors will NOT be allowed to submit disclosures on a co-author's behalf.